Navigation Links
New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly,Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer,Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by,Paclitaxel

22 US Oncology Affiliated Physicians Participate in ASCO Proceedings

HOUSTON, June 04, 2007 /PRNewswire/ -- A leading cancer researcher affiliated with the US Oncology Research Network presented findings from a randomized, multicenter phase III trial that compared the disease-free survival (DFS) obtained with two regimens of adjuvant therapy for patients with high-risk breast cancer.

The study results were given in an oral presentation by Dr. David Loesch of Central Indiana Cancer Centers, at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) held June 2-5, 2007 in Chicago. Dr. Loesch is the lead investigator and a member of US Oncology's breast cancer research committee.

The study, titled "A randomized, multicenter phase III trial comparing doxorubicin plus cyclophosphamide followed by paclitaxel or doxorubicin plus paclitaxel followed by weekly paclitaxel as adjuvant therapy for high risk breast cancer" (abstract number 517) was conducted among women with local, operable, confirmed stage I-III adenocarcinoma, who had primary surgery, with no residual tumor.

The research found that Therapy Arm 2 (ATT) (doxorubicin 50 mg/m2 plus paclitaxel 200 mg/m2 repeated every three weeks for four cyclespaclitaxel 80 mg/m2 weekly x12) AT+WP can be considered equal to ACT as a standard treatment in the community. It has more peripheral neuropathy than ACT; but the neuropathy is reversible. In a repeat analysis of the triple negative subgroup, APWP was superior to ACT in overall survival (OS).

In addition, 22 physicians and researchers affiliated with US Oncology participated in oral and poster presentations, moderated panels and published studies at this year's ASCO conference in Chicago. The researchers presented findings on a variety of disease states including lung, gastrointestinal, genitourinary, gynecologic, breast and melanoma.

    -- Daniel Von Hoff, M.D.
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:9/19/2014)... 2014 /PRNewswire-iReach/ -- "United States General ... key market data on the United ... report provides value, in millions of ... within market categories – Bronchoscopes, Laryngoscopes, ... Gastroscopes, Duodenoscopes, Laparoscopes, Hysteroscopes, Sinuscopes, Resectoscopes, ...
(Date:9/19/2014)... CHICAGO, Ill. , Sept. 19, 2014  The ... ABBV ) declared a quarterly cash dividend of $0.42 ... payable Nov. 17, 2014 to stockholders of record at ... About AbbVie AbbVie is a global, research-based biopharmaceutical ... company,s mission is to use its expertise, dedicated people ...
(Date:9/19/2014)... 19, 2014  4WEB Medical announces the formal launch ... ankle osteotomy implants on the market today at ... meeting in Chicago .  The Osteotomy ... osteotomy needs with 74 size options included in one ... of only 15 to 18 implant sizes, which limited ...
Breaking Medicine Technology:United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 3United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 4United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 54WEB Medical Unveils 3D-Printed Osteotomy Truss System 2
... Ga. and TRENTON, N.J., April 18, 2012 Kimberly-Clark ... cleanrooms and laboratories, and TerraCycle, a leading recycler, today ... and laboratory garment recycling initiative to include a pilot ... the program,s first six months. Since the ...
...  UCB, a leading biopharmaceutical company committed to the development ... sets of key epilepsy data at the 64th Annual ... New Orleans from April 21-28.  The data comprise several ... Vimpat® (lacosamide) C-V, including updated health-related quality of life ...
Cached Medicine Technology:Kimberly-Clark Professional* and TerraCycle Expand Industry's First Cleanroom and Laboratory Garment Recycling Initiative to Include Pilot Program for Gloves 2Kimberly-Clark Professional* and TerraCycle Expand Industry's First Cleanroom and Laboratory Garment Recycling Initiative to Include Pilot Program for Gloves 3Kimberly-Clark Professional* and TerraCycle Expand Industry's First Cleanroom and Laboratory Garment Recycling Initiative to Include Pilot Program for Gloves 4UCB Sponsors Data Presentations on Epilepsy and Vimpat® (lacosamide) C-V at the 64th Annual Meeting of the American Academy of Neurology 2UCB Sponsors Data Presentations on Epilepsy and Vimpat® (lacosamide) C-V at the 64th Annual Meeting of the American Academy of Neurology 3UCB Sponsors Data Presentations on Epilepsy and Vimpat® (lacosamide) C-V at the 64th Annual Meeting of the American Academy of Neurology 4UCB Sponsors Data Presentations on Epilepsy and Vimpat® (lacosamide) C-V at the 64th Annual Meeting of the American Academy of Neurology 5UCB Sponsors Data Presentations on Epilepsy and Vimpat® (lacosamide) C-V at the 64th Annual Meeting of the American Academy of Neurology 6UCB Sponsors Data Presentations on Epilepsy and Vimpat® (lacosamide) C-V at the 64th Annual Meeting of the American Academy of Neurology 7UCB Sponsors Data Presentations on Epilepsy and Vimpat® (lacosamide) C-V at the 64th Annual Meeting of the American Academy of Neurology 8UCB Sponsors Data Presentations on Epilepsy and Vimpat® (lacosamide) C-V at the 64th Annual Meeting of the American Academy of Neurology 9
(Date:9/19/2014)... AZ (PRWEB) September 19, 2014 Hastings and ... 30 years in the industry, announces a record number of ... handles a wide variety of serious injury cases as well ... along with dog bite related accident cases and others. Having ... and Hastings has stood the test of time when it ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Visiting Nurse ... of home health care, hospice and palliative care and ... ring the Opening Bell yesterday at the New York ... Jersey philanthropist and social entrepreneur to care for immigrant ... Group has always worked to meet the urgent healthcare ...
(Date:9/19/2014)... 19, 2014 Boston Scientific Corp. has ... ( http://www.transvaginalmeshlawsuithelp.com/ ) that is scheduled to go ... Liebhard LLP reports. According to a Motion ... company asserts that claims involving its Solyx pelvic mesh ... Remedies Code, a section of which shields manufacturers ...
(Date:9/19/2014)... Your brain structure could help predict how willing you are ... at Yale University found those with greater volume in a ... be more likely to engage in risky behavior than people ... funded by the U.S. National Institute on Aging, involved two ... Northeast. The researchers sought to determine how brain structure influences ...
(Date:9/19/2014)... Although there is mounting evidence that muscle-strength training ... adults in the United States don,t engage in ... Less than one-quarter of adults over 45 ... of Health and Human Services, the study found. ... and fitness and staying independent, researchers advised. Muscle-strengthening ...
Breaking Medicine News(10 mins):Health News:Hastings And Hastings Announces a Record Number of Visitors to Its New Phoenix Personal Injury Website 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 3Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 4Health News:Brain Structure Might Help Predict Risky Behavior 2Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2
... Interfere with Prescribed TherapiesSACRAMENTO, Calif., May 11 The ... a national network of over 250 physicians with the ... approved medical treatments and therapies, today cited a recent ... a large number of physicians believe insurance companies are ...
... announced today that for the quarter ended March 31, 2009, it ... share, on revenues of $5.2 million compared to a net loss ... $5.2 million in the previous year. The loss from continuing operations ... to income of $3.2 million for the same period in 2008. ...
... 11, 2009; 3 pm Central Daylight Time) Many ... into the office complaining of chest pain, undergoes a stress ... results suggest coronary artery disease, a condition in which plaque ... for an angiogram to look at the coronary arteries and ...
... available in French . , Montreal, May ... not have been dealt an equal hand. The latest study ... McGill University Health Centre and McGill University, shows that women ... the production of estrogen by females could have a beneficial ...
... Trust Incorporated (NYSE: HR ) today announced results ... from operations ("FFO") per diluted common share for the three ... for the three months ended March 31, 2008. FFO ... three months ended March 31, 2009, before the recognition of ...
... (NYSE: HR ) today announced its common stock ... This dividend, in the amount of $0.385 per share, is ... May 22, 2009. The total dividend of $22.8 million ... in accordance with GAAP. The Company,s cash flow statement ...
Cached Medicine News:Health News:Alliance for Patient Access Wants Health Care Code of Conduct 2Health News:Westaim announces 2009 first quarter results 2Health News:Westaim announces 2009 first quarter results 3Health News:Study: Women with hard to diagnose chest pain symptoms at higher risk for cardiovascular events 2Health News:Study: Women with hard to diagnose chest pain symptoms at higher risk for cardiovascular events 3Health News:Equality of the sexes? Not always when it comes to biology 2Health News:Healthcare Realty Trust Announces First Quarter Results 2Health News:Healthcare Realty Trust Announces First Quarter Results 3Health News:Healthcare Realty Trust Announces First Quarter Results 4Health News:Healthcare Realty Trust Announces First Quarter Results 5Health News:Healthcare Realty Trust Announces First Quarter Results 6Health News:Healthcare Realty Trust Announces First Quarter Results 7Health News:Healthcare Realty Trust Announces First Quarter Results 8Health News:Healthcare Realty Trust Announces First Quarter Results 9Health News:Healthcare Realty Trust Announces First Quarter Dividend 2Health News:Healthcare Realty Trust Announces First Quarter Dividend 3Health News:Healthcare Realty Trust Announces First Quarter Dividend 4
... features including aspiration holes and additional ... procedures requiring precise dissection with decreased ... suction demands. ,Flexible design options ... nonretractable electrodes and multiple tip designs. ...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
Medicine Products: